Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 6, 2015, Pages 451-467

  Lu, Jing ^a   Lee Gabel, Linda ^a   Nadeau, Michelle C ^a   Ferencz, Thomas M ^a   Soefje, Scott A ^b  

^a Smilow Cancer Hospital at Yale New Haven   (United States)

^b University Medical Center Brackenridge   (United States)

Author keywords

Antiprogrammed death 1 programmed death ligand 1; BMS 936559; CTLA 4 blockade; immune related adverse event; ipilimumab; management of adverse events; MEDI4736; MK 3475; MPDL3280A; MSB0010718C; nivolumab; pidilizumab

Indexed keywords

ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; AVELUMAB; BMS 936559; CORTICOSTEROID; DEXAMETHASONE; DIPHENOXYLATE; DURVALUMAB; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; IPILIMUMAB; LEVOTHYROXINE; LOPERAMIDE; METHYLPREDNISOLONE; MINERALOCORTICOID; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY;

ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; CANCER IMMUNOTHERAPY; CHILL; CLINICAL EVALUATION; COLITIS; CONSTIPATION; CORTICOSTEROID THERAPY; COUGHING; CYTOKINE STORM; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ENDOCRINE DISEASE; EYE DISEASE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HALF LIFE TIME; HEADACHE; HEPATITIS; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFUSION RELATED REACTION; INSOMNIA; LIVER DISEASE; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OCCUPATIONAL HAZARD; OPPORTUNISTIC INFECTION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR LYSIS SYNDROME; VITILIGO; VOLUME OF DISTRIBUTION; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; T LYMPHOCYTE; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84945293157     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214538087     Document Type: Review

References (100)

1. Mellman I, Coukos G, Dranoff G,. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489.
2. Maslin B, Alexandrescu DT, Ichim TE, et al. Newer developments in the immunotherapy of malignant melanoma. J Oncol Pharm Pract 2014; 20 (1): 3-10.
3. Drake CG, Lipson EJ, Brahmer JR,. Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11 (1): 24-37.
4. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-3679.
5. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
6. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
7. Chen L,. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-347.
8. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37: 533-546.
9. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
10. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
11. Lipson EJ, Drake CG,. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17: 6958-6962.
12. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008 26 Suppl. Abstr 9011.
13. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
14. O'Day S, Hodi FS, McDermott DF, et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol 2010; 29 Suppl: Abstr 4.
15. Drake CG, Jaffee E, Pardoll DM,. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
16. www.immunooncology.com/home.aspx.
17. Roettger W. 2013 CI Briefing-Nivolumab. http://www.slideshare.net/wroettger/oncology-immunotherapy-nivolumab-and-other-pd1pdl1-targeted-agents-061213.
18. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
19. Sznol M, Kluger HM, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013 31 Suppl. Abstr CRA9006.
20. Brahmer JR, Horn L, Antonia SJ, et al. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2013 31 Suppl. Abstr 8030.
21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
22. Topalian SL, Sznol M, Brahmer JR, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. J Clin Oncol 2013 31 Suppl. Abstr 3002.
23. Brahmer JR, Horn L, Antonia S, et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2012 30 suppl. Abstr 7509.
24. Merelli B, Massi D, Cattaneo L, et al. Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014; 89: 140-165.
25. Khleif S, Lutzky J, Segal N, et al. MEDI4736, an anti-PD-L1 antibody with modified Fc domain: Preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors. Proc Eur Cancer Congr 2013. Abstr 802.
26. www.researchandmarkets.com/reports/2537740/merck-kgaa-product-pipeline-review-2013.pdf.
27. Hardy B, Kovjazin R, Raiter A, et al. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc Natl Acad Sci U S A 1997; 94 (11): 5756-5760.
28. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT00441337 (2013).
29. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT00730639 (2013).
30. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01454102 (2013).
31. Rizvi NA, Antonia SJ, ChowA LQ, et al. Phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013 31 Suppl. Abstr 8072.
32. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01642004 (2013).
33. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01673867 (2013).
34. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01721746 (2013).
35. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01024231 (2013).
36. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369 (2): 122-133.
37. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01844505 (2013).
38. Hamid O, Rovert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
39. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
40. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01295827 (2011).
41. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01840579 (2013).
42. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01905657 (2013).
43. Garon EB, Balmanoukian A, Hamid O, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). In: 15th world conference on lung cancer, Sydney, Australia: October, Abstr 2416, 2013, pp. 27-30.
44. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT02007070 (2013).
45. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01866319 (2013).
46. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01704287 (2012).
47. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01848834 (2013).
48. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01876511 (2013).
49. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01953692 (2013).
50. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT02014636 (2013).
51. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-3051.
52. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013; 31: 4199-4206.
53. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/ NCT01435369 (2013).
54. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT00890305 (2013).
55. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT00904722 (2013).
56. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01952769 (2013).
57. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT00962936 (2013).
58. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT00966251 (2013).
59. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01313416 (2013).
60. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01420965 (2013).
61. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01096602 (2013).
62. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01067287 (2013).
63. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01441765 (2013).
64. Herbst RS, Gordon MS, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 2013 31 Suppl. Abstr 3000.
65. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT01375842 (2011).
66. Hamid O, Sosan JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma. J Clin Oncol 2013 31 Suppl. Abstr 9010.
67. Cho DC, Sosamn JA, Sznol M, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma. J Clin Oncol 2013 31 Suppl. Abstr 4505.
68. www.esmo.org/Conferences/Past-Conferences/European-Cancer-Congress-2013/News/ECC-2013-Press-Release-Promising-Results-for-New-Antibody-Drug-in-Non-Small-Cell-Lung-Cancer-Patients-Smokers-Respond-Well. ECC 2013 Press Release, 29 September 2013 Amsterdam, The Netherlands.
69. US National Library of Medicine.Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01656642 (2012).
70. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01846416 (2013).
71. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01903993 (2013).
72. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01984242 (2013).
73. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01988896 (2013).
74. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT02008227 (2013).
75. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT02013219 (2013).
76. Tykodi SS, Brahmer JR, Hwu J, et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. J Clin Oncol 2012 30 suppl. Abstr 2510.
77. Creelan BC,. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014; 21: 80-89.
78. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01693562 (2012).
79. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01938612 (2013).
80. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT02027961 (2013).
81. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01975831 (2013).
82. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT02000947 (2013).
83. www.biocentury.com/products/anti-pd-l1.
84. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01772004 (2013).
85. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01943461 (2013).
86. Brennan FR, Morton LD, Spindeldreher S, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. Mabs 2010; 2: 233-255.
87. Tarhini A,. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica (Cairo) 2013; 2013: 857519.
88. www.uptodate.com/contents/immunotherapy-of-advanced-melanoma-with-immune-checkpoint-inhibition.
89. YERVOY (ipilimumab): serious and fatal immune-mediated adverse reactions, Ipilimumab US prescribing information: risk evaluation and mitigation strategy (REMS), Bristol-Myers Squibb 2012; www.yervoy.com/hcp/rems.aspx.
90. Weber JS, Kähler KC, Hauschild A, et al. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697.
91. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/adult-oi.pdf.
92. Yazaki H, Goto N, Uchida K, et al. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009; 88: 380-385.
93. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 700-705.
94. St Clair EW,. The calm after the cytokine storm: Lessons from the TGN1412 trial. J Clin Invest 2008; 118 (4): 1344-1347.
95. www.emedicine.medscape.com/article/282171-treatment Tumor Lysis Syndrome Treatment & Management.
96. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26: 2767-2778.
97. www.medscape.com/viewarticle/813526#2. Exciting times with immunotherapy in lung cancer. 5th World Conference on Lung Cancer (WCLC) 2013; Abstr M18.01 (MPDL-3280A), M18.02 (MK-3475), and M18.03 (nivolumab).
98. Kang SP, Saif MW,. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-identification prevention and management. J Support Oncol 2007; 5: 451-457.
99. www.slideshare.net/wroettger/oncology-immunotherapy-nivolumab-and-other-pd1pdl1-targeted-agents-061213?utm-source=slideshow02&utm-medium=ssemail&utm-campaign=share-slideshow.
100. Zitvogel L, Kroemer G,. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1: 1223-1225.